Methylenedioxytrimethylamphetamine
Chemical compound
| Methylenedioxytrimethylamphetamine | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Methylenedioxytrimethylamphetamine (MDTA) is a psychoactive drug of the amphetamine class. It is a derivative of methylenedioxyamphetamine (MDA) and is chemically related to methylenedioxymethamphetamine (MDMA), commonly known as ecstasy. MDTA is known for its stimulant and hallucinogenic effects, although it is less well-known and less studied than its more famous relatives.
Chemical structure and properties[edit]

MDTA is a member of the substituted amphetamines class, characterized by the presence of a methylenedioxy group attached to the phenyl ring. The chemical structure of MDTA is similar to that of MDMA, with the primary difference being the presence of an additional methyl group on the nitrogen atom. This structural modification influences the drug's pharmacological properties and its interaction with neurotransmitter systems in the brain.
Pharmacology[edit]
MDTA acts primarily as a serotonin and dopamine releasing agent. It increases the levels of these neurotransmitters in the synaptic cleft by promoting their release from presynaptic neurons and inhibiting their reuptake. This action is responsible for the drug's mood-enhancing and stimulant effects. The increased serotonin levels can lead to feelings of euphoria, emotional closeness, and altered sensory perception, while the increased dopamine levels contribute to increased energy and alertness.
Effects[edit]
The effects of MDTA are similar to those of other entactogens and stimulants. Users may experience:
- Euphoria
- Increased sociability and empathy
- Enhanced sensory perception
- Increased energy and alertness
- Mild hallucinations
The duration of effects typically lasts between 4 to 6 hours, depending on the dose and individual metabolism.
Risks and side effects[edit]
As with other psychoactive substances, the use of MDTA carries potential risks and side effects. These may include:
- Increased heart rate and blood pressure
- Anxiety and paranoia
- Insomnia
- Jaw clenching and teeth grinding
- Nausea
Long-term use or high doses can lead to more severe health issues, including neurotoxicity and serotonin syndrome.
Legal status[edit]
MDTA is classified as a controlled substance in many countries due to its potential for abuse and lack of medical use. It is illegal to manufacture, possess, or distribute MDTA without a license or prescription.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian